Currently, Tumor Treating Fields (TTF) are delivered using two static arrays positioned opposite each other on the body. Each array consists of multiple specialized ceramic discs, known as array elements. When activated, both arrays are energized simultaneously—one positive, the other negative—creating an electric field (or coupling) that passes through the body. Importantly, no electrical current comes into contact with the skin.
click on image to view larger
click on image to view larger
The diagram below illustrates the effective shape of a Tumor Treating Field as it passes through a homogeneous material, representing a cross-section of the human body (tissue variations have been removed for clarity).
The dark magenta region represents a TTF strong enough to kill cancer cells, while the yellow and blue areas indicate insufficient field strength. In this simulation, any cancer outside the magenta zone would remain untreated. To reach tumors beyond the central target, the arrays would need to be physically repositioned. However, moving them simply creates new weak spots, failing to provide consistent coverage. This limitation explains why static TTF works well for localized tumors but is far less effective for treating diffuse or widespread cancer, especially in late-stage patients.
As shown below, adding more static arrays eventually fails—targeting new tumor sites would require overlapping arrays, which isn’t physically possible.
LifeBridge Innovations addresses this challenge with its patented programmable disc technology. The LB10000 TTF system enables dynamic reassignment of array elements, allowing the discs to be programmed to target virtually any area of the body.
TTF waves or sweeps can be delivered across the entire abdomen, with the ability to form multiple fields simultaneously in some cases. Unlike static TTF, the most powerful part of the field can be dynamically directed to all accessible areas.
Preclinical research demonstrates that TTF delivery that briefly pauses and restarts within three seconds maintains the same cancer-killing effectiveness as a continuous TTF.